SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107. A total of 102 filers reported holding SYROS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.76 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $7,000 | -91.5% | 916 | -90.3% | 0.00% | -100.0% |
| Q3 2020 | $82,000 | +925.0% | 9,419 | +668.9% | 0.01% | – |
| Q4 2019 | $8,000 | +300.0% | 1,225 | +531.4% | 0.00% | – |
| Q3 2019 | $2,000 | -33.3% | 194 | -29.5% | 0.00% | – |
| Q1 2019 | $3,000 | 0.0% | 275 | -53.0% | 0.00% | – |
| Q4 2018 | $3,000 | +200.0% | 585 | +446.7% | 0.00% | – |
| Q3 2018 | $1,000 | -99.9% | 107 | -9.3% | 0.00% | – |
| Q2 2018 | $1,205,000 | +60150.0% | 118 | -16.3% | 0.00% | – |
| Q1 2018 | $2,000 | -33.3% | 141 | -59.4% | 0.00% | – |
| Q4 2017 | $3,000 | +200.0% | 347 | +580.4% | 0.00% | – |
| Q3 2017 | $1,000 | -75.0% | 51 | -78.9% | 0.00% | – |
| Q2 2017 | $4,000 | 0.0% | 242 | 0.0% | 0.00% | – |
| Q1 2017 | $4,000 | +300.0% | 242 | +152.1% | 0.00% | – |
| Q4 2016 | $1,000 | – | 96 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 3,139,895 | $23,486,000 | 4.50% |
| Samsara BioCapital, LLC | 2,189,199 | $14,769,000 | 2.72% |
| Bain Capital Life Sciences Investors, LLC | 5,785,036 | $43,272,000 | 2.45% |
| Omega Fund Management, LLC | 1,562,500 | $11,688,000 | 1.11% |
| Flagship Pioneering Inc. | 2,938,494 | $21,980,000 | 0.35% |
| EcoR1 Capital, LLC | 1,000,000 | $7,480,000 | 0.33% |
| Altium Capital Management LP | 126,702 | $948,000 | 0.26% |
| Nikko Asset Management Americas, Inc. | 5,042,009 | $37,714,000 | 0.18% |
| Artal Group S.A. | 1,025,000 | $7,667,000 | 0.14% |
| Orbimed Advisors | 1,837,500 | $13,745,000 | 0.13% |